Evidence brief
TB-500: Research evidence and Canadian regulatory context
This educational profile distinguishes laboratory and preclinical discussion from clinical conclusions. It does not provide a treatment, administration, dosing, sourcing, or product-quality recommendation.
Evidence maturity: limited human data specific to TB-500; preclinical discussion dominates.
Human evidence
The cited sports-medicine review reports that human orthopaedic data for thymosin-beta-4 and TB-500 are lacking. A lack of human orthopaedic data is not evidence of clinical benefit or safety.
Preclinical context
The review summarizes angiogenesis and tissue-repair observations in preclinical models. Those observations should be read as research context, not as proof of an outcome for a person, injury, or condition.
What remains unknown
Clear human indications, controlled clinical trials, reliable safety characterization, and evidence-based information on administration, frequency, or duration are not established by the cited review.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| limited human data specific to TB-500; preclinical discussion dominates. | The cited sports-medicine review reports that human orthopaedic data for thymosin-beta-4 and TB-500 are lacking. A lack of human orthopaedic data is not evidence of clinical benefit or safety. | Clear human indications, controlled clinical trials, reliable safety characterization, and evidence-based information on administration, frequency, or duration are not established by the cited review. |
Canadian regulatory context
Health Canada’s public advisory describes general risks of unauthorized injectable peptide drugs. It does not establish a clinical use, product quality standard, or individualized safety conclusion for TB-500.
Evidence timeline
- 1
Early research: thymosin-beta-4 biology and preclinical questions
- 2
Human literature: limited and not specific to orthopaedic TB-500 outcomes
- 3
Current: controlled human outcome and safety gaps remain
How to read this evidence brief
Population first
Start with the studied population and protocol before interpreting an outcome. A result in a defined disease group does not automatically generalize to other readers.
Outcome second
Separate measured endpoints from broader claims about health, performance, product quality, or long-term benefit.
Limitations remain visible
The evidence gaps and regulatory context are part of the record, not footnotes to be ignored.
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- Injectable peptide therapy review (2026)
Narrative review describing the absence of human orthopaedic data for TB-4/TB-500.
- Health Canada public advisory
Official Canadian information on unauthorized injectable peptide drugs.